Analytical Data
-
Gene name
ECRG4
- Application
-
Alternative Names
C2orf40; Augurin
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H1Z8
-
Expression Region
Asn32~Tyr148
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ECRG4, or "Enhanced Cationic Repeat Gene 4," is a gene that has garnered significant interest in the field of cancer research due to its potential role as a tumor suppressor. Initially identified through its downregulation in various malignancies, ECRG4 has been linked to processes such as cell proliferation, apoptosis, and metastasis. Studies suggest that ECRG4 may inhibit cancer progression by modulating signaling pathways associated with cell growth and survival. Its expression levels have been inversely correlated with tumor aggressiveness in several types of cancer, including gastric and colorectal cancers. Given the protein's involvement in the regulation of cellular mechanisms, research has focused on elucidating its functional properties and the molecular pathways it influences. Furthermore, the therapeutic potential of ECRG4 as a biomarker for early diagnosis and a candidate for targeted therapy is currently being explored. Understanding ECRG4's biological functions and its interaction with other cellular components is crucial for developing new strategies in cancer treatment and prevention, making it a promising subject for ongoing and future research endeavors.
